Concert Pharmaceuticals (CNCE) Receives News Sentiment Rating of 0.15

News coverage about Concert Pharmaceuticals (NASDAQ:CNCE) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.880364940854 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment’s scoring:

A number of equities research analysts recently commented on CNCE shares. BidaskClub downgraded Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, December 22nd. UBS Group set a $34.00 target price on Concert Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 19th. TheStreet raised Concert Pharmaceuticals from a “d” rating to a “c+” rating in a report on Wednesday, November 29th. Zacks Investment Research raised Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Concert Pharmaceuticals in a report on Friday, November 10th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Concert Pharmaceuticals has an average rating of “Buy” and a consensus price target of $24.83.

Concert Pharmaceuticals (CNCE) opened at $25.46 on Thursday. Concert Pharmaceuticals has a twelve month low of $8.61 and a twelve month high of $30.71. The stock has a market capitalization of $582.98, a P/E ratio of 6.84 and a beta of 1.67.

In related news, insider Value Fund L. P. Biotechnology purchased 331,916 shares of the firm’s stock in a transaction on Thursday, October 19th. The stock was bought at an average cost of $15.84 per share, with a total value of $5,257,549.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $26.65, for a total value of $34,188,112.40. The disclosure for this sale can be found here. Insiders own 10.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Concert Pharmaceuticals (CNCE) Receives News Sentiment Rating of 0.15” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/28/concert-pharmaceuticals-cnce-receives-news-sentiment-rating-of-0-15.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Insider Buying and Selling by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

What are top analysts saying about Concert Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Concert Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit